Literature DB >> 2173167

Determination of plasma protein C inhibitor and of two activated protein C-inhibitor complexes in normals and in patients with intravascular coagulation and thrombotic disease.

F España1, V Vicente, D Tabernero, I Scharrer, J H Griffin.   

Abstract

We developed an ELISA to quantitate complexes of activated protein C (APC) with a major plasma APC inhibitor, alpha 1-antitrypsin (alpha 1AT) in human plasma based on the sandwich principle using two different antibodies directed towards protein C and alpha 1AT, respectively. This ELISA test was specific for APC:alpha 1AT complexes and sensitive to greater than or equal to 150 pg complex. Fifty-one of 56 healthy donors had APC:alpha 1AT complex levels above the detection limit (3 ng/ml) ranging from 4 to 14 ng/ml (mean value +/- SD: 7.6 +/- 2.5 ng/ml). Patients (n = 10) with disseminated intravascular coagulation (DIC) had detectable levels of APC:alpha 1AT complex ranging from 21 to 125 ng/ml (median: 69 ng/ml). Complexes of APC with plasma protein C inhibitor (PCI) were also measured using an ELISA sandwich assay. None of the 30 healthy donors had detectable levels (greater than or equal to 5 ng/ml) of APC:PCI complex, and plasma samples from 9 of 10 DIC patients had detectable concentrations of APC:PCI complex ranging from 10 to 63 ng/ml (median: 22 ng/ml). APC:alpha 1AT complex was detected in 25 of 26 patients with deep venous thrombosis (DVT), with levels ranging from 5 to 136 ng/ml (median: 23 ng/ml), whereas APC:PCI was detected in only 6 DVT patients, with levels between 11 and 105 ng/ml. PCI antigen levels in 70 normals ranged from 56 to 175% (mean +/- SD: 99.1% +/- 24.2%). PCI antigen levels were decreased in DIC patients, in patients with cerebral arterial thrombosis, and in DVT patients undergoing heparin therapy, but not in patients with myocardial infarction. PCI antigen levels were decreased much further in DVT patients receiving heparin compared to those not receiving heparin, showing that heparin therapy is associated with a decrease in PCI levels. The detection in normal subjects and in thrombotic patients of circulating APC:inhibitor complexes supports the view that the protein C pathway is activated during DIC and DVT. Moreover, it emphasizes that both PCI and alpha 1AT are physiologic inhibitors of APC. Thus, measurement of APC complexes may provide sensitive parameters for specific detection of activation of the clotting and protein C pathways.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2173167     DOI: 10.1016/0049-3848(90)90418-c

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  9 in total

1.  Laboratory Measurement of Thrombin Activity--What Every Clinician Scientist Needs to Know.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

2.  The diagnostic performance of APC-PCI complex determination compared to D-dimer in the diagnosis of deep vein thrombosis.

Authors:  Johan L Elf; Karin Strandberg; Peter J Svensson
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

Review 3.  New biological concepts on coagulation inhibitors.

Authors:  N Sala; J Fontcuberta; M L Rutllant
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

4.  α2-Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC:α2M Levels Are Associated with Venous Thromboembolism.

Authors:  Laura Martos; Luis Andrés Ramón; Julia Oto; Álvaro Fernández-Pardo; Santiago Bonanad; Ana Rosa Cid; Andras Gruber; John H Griffin; Francisco España; Silvia Navarro; Pilar Medina
Journal:  Thromb Haemost       Date:  2018-02-15       Impact factor: 5.249

5.  Activated protein C plasma levels in the fasting and postprandial states among patients with previous unprovoked venous thromboembolism.

Authors:  John-Bjarne Hansen; José A Fernández; Knut H Borch; John H Griffin; Jan H Brox; Sigrid K Braekkan
Journal:  Thromb Res       Date:  2011-07-20       Impact factor: 3.944

6.  Explorative investigation of biomarkers of brain damage and coagulation system activation in clinical stroke differentiation.

Authors:  Johan Undén; Karin Strandberg; Jan Malm; Eric Campbell; Lars Rosengren; Johan Stenflo; Bo Norrving; Bertil Romner; Arne Lindgren; Gunnar Andsberg
Journal:  J Neurol       Date:  2009-02-09       Impact factor: 4.849

7.  Therapeutic levels of human protein C in rats after retroviral vector-mediated hepatic gene therapy.

Authors:  S R Cai; S C Kennedy; W M Bowling; M W Flye; K P Ponder
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

8.  Protein C inhibitor is expressed in tubular cells of human kidney.

Authors:  K P Radtke; J A Fernández; J S Greengard; W W Tang; C B Wilson; D J Loskutoff; I Scharrer; J H Griffin
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

9.  Phospholipid Binding Protein C Inhibitor (PCI) Is Present on Microparticles Generated In Vitro and In Vivo.

Authors:  Katrin Einfinger; Sigrun Badrnya; Margareta Furtmüller; Daniela Handschuh; Herbert Lindner; Margarethe Geiger
Journal:  PLoS One       Date:  2015-11-18       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.